Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is comparing 2 formulations of bosutinib in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Commercial Tablet manufactured by Excella |
|
| 2 | Experimental | Clinical Tablet manufactured by Wyeth Montreal |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SKI-606 (Bosutinib) | Drug | Arm 1 - Commercial Tablet manufactured by Excella Arm 2 - Clinical Tablet manufactured by Wyeth Montreal |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics as measured by Cmax, AUC, tmax, and t1/2 | 2 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Wyeth is now a wholly owned subsidiary of Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tacoma | Washington | 98418 | United States |
Not provided
| ID | Term |
|---|---|
| C471992 | bosutinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided